CAR-T cell therapy for relapsed or refractory osteosarcoma
Part of Cancer clinical trials.
This trial tests a new CAR-T cell treatment called IM83 for people with osteosarcoma in their arms or legs that has come back or not responded to standard chemotherapy. The goal is to see if it can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years or older.
- You must have osteosarcoma in an arm or leg that has come back or not responded to standard chemotherapy.
- Your cancer must not be able to be removed by surgery or treated with localized therapy.
- You must have a tumor sample that tests positive for a protein called GPC3.
- You must be in reasonably good health, with normal blood counts, kidney function, and heart function.
- You cannot have received certain other types of cell therapy before, like CAR-T or TCR-T.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new type of immune cell therapy (4th generation CAR T cells) designed to recognize and attack sarcoma cells. It's for people with advanced or recurrent sarcoma whose tumors have a specific marker.
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
This trial tests a combination of immune cells targeting sarcoma tumors. It is for people with advanced or recurrent sarcoma who have not responded well to standard treatments.
Hear when a new Refractory Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.